Skip to main content

Oncology

Featured

News
08/13/2026
Stephanie Holland
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated...
08/13/2026
Oncology
News
08/12/2026
Stephanie Holland
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3...
08/12/2026
Oncology
News
08/12/2026
Emily Estrada
Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...
Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...
Results from the phase 1b/2...
08/12/2026
Oncology
News
08/12/2026
Emily Estrada
Long-term results from the phase 3 FeDeriCa trial showed that fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy and a comparable safety profile versus intravenous therapy in HER2-positive early breast cancer, supporting...
Long-term results from the phase 3 FeDeriCa trial showed that fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy and a comparable safety profile versus intravenous therapy in HER2-positive early breast cancer, supporting...
Long-term results from the phase...
08/12/2026
Oncology
Craig L. Slingluff, Jr., MD
Videos
08/12/2026
Craig Slingluff, MD
Craig Slingluff, MD, discusses long-term follow-up from a multicenter melanoma vaccine trial showing that two-site peptide vaccine administration improved recurrence-free survival while adding GM-CSF did not enhance clinical outcomes,...
Craig Slingluff, MD, discusses long-term follow-up from a multicenter melanoma vaccine trial showing that two-site peptide vaccine administration improved recurrence-free survival while adding GM-CSF did not enhance clinical outcomes,...
Craig Slingluff, MD, discusses...
08/12/2026
Oncology
News
08/12/2026
Stephanie Holland
A multicenter diagnostic study found that a modern artificial intelligence (AI) foundation model outperformed physicians with fewer than 3 years of dermatology experience and matched midcareer clinicians in skin cancer diagnosis but remained...
A multicenter diagnostic study found that a modern artificial intelligence (AI) foundation model outperformed physicians with fewer than 3 years of dermatology experience and matched midcareer clinicians in skin cancer diagnosis but remained...
A multicenter diagnostic study...
08/12/2026
Oncology
News
08/12/2026
Stephanie Holland
Long-term results from a randomized phase 2 trial showed that administering a 12-peptide melanoma vaccine at 2 injection sites significantly improved recurrence-free survival in patients with resected high-risk melanoma, whereas adding GM-CSF...
Long-term results from a randomized phase 2 trial showed that administering a 12-peptide melanoma vaccine at 2 injection sites significantly improved recurrence-free survival in patients with resected high-risk melanoma, whereas adding GM-CSF...
Long-term results from a...
08/12/2026
Oncology
News
08/12/2026
Emily Estrada
Results from a phase 1/2 study showed that sonrotoclax monotherapy produced rapid and durable responses with a manageable safety profile in patients with relapsed or refractory mantle cell lymphoma previously treated with anti-CD20–based...
Results from a phase 1/2 study showed that sonrotoclax monotherapy produced rapid and durable responses with a manageable safety profile in patients with relapsed or refractory mantle cell lymphoma previously treated with anti-CD20–based...
Results from a phase 1/2 study...
08/12/2026
Oncology
News
08/11/2026
Emily Estrada
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab...
08/11/2026
Oncology
Sikander Ailawadhi, MD
Videos
08/07/2026
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD,...
08/07/2026
Oncology
FDA Approval
08/06/2026
Emily Estrada
The FDA has granted accelerated approval to vusolimogene oderparepvec plus nivolumab for patients with unresectable advanced cutaneous melanoma that has progressed following PD-1-blockade, based on durable responses observed in the phase 2...
The FDA has granted accelerated approval to vusolimogene oderparepvec plus nivolumab for patients with unresectable advanced cutaneous melanoma that has progressed following PD-1-blockade, based on durable responses observed in the phase 2...
The FDA has granted accelerated...
08/06/2026
Oncology

Videos

Craig L. Slingluff, Jr., MD
Videos
08/12/2026
Craig Slingluff, MD
Craig Slingluff, MD, discusses long-term follow-up from a multicenter melanoma vaccine trial showing that two-site peptide vaccine administration improved recurrence-free survival while adding GM-CSF did not enhance clinical outcomes,...
Craig Slingluff, MD, discusses long-term follow-up from a multicenter melanoma vaccine trial showing that two-site peptide vaccine administration improved recurrence-free survival while adding GM-CSF did not enhance clinical outcomes,...
Craig Slingluff, MD, discusses...
08/12/2026
Oncology
Sikander Ailawadhi, MD
Videos
08/07/2026
Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD, discusses results from the phase 3 IRAKLIA trial showing that subcutaneous isatuximab administered via on-body injector demonstrated noninferior efficacy and pharmacokinetics compared with intravenous isatuximab while...
Sikander Ailawadhi, MD,...
08/07/2026
Oncology
Barbara Burtness, MD
Videos
08/06/2026
Barbara Burtness, MD, FASCO
Barbara Burtness, MD, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in previously treated HPV-negative head and neck squamous cell carcinoma, highlighting encouraging response rates,...
Barbara Burtness, MD, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab in previously treated HPV-negative head and neck squamous cell carcinoma, highlighting encouraging response rates,...
Barbara Burtness, MD, discusses...
08/06/2026
Oncology
Videos
08/05/2026
Jamie Chaft, MD
In this video, Jamie Chaft, MD, discusses why biomarker testing in NSCLC should be reassessed over time as clinical questions evolve across diagnosis, treatment response, progression, and later-line decision-making. She highlights the role of...
In this video, Jamie Chaft, MD, discusses why biomarker testing in NSCLC should be reassessed over time as clinical questions evolve across diagnosis, treatment response, progression, and later-line decision-making. She highlights the role of...
In this video, Jamie Chaft, MD,...
08/05/2026
Oncology
Videos
08/05/2026
Jamie Chaft, MD
In this video, Jamie Chaft, MD, explains why “MET-positive” is not a single biological category and why clinicians should distinguish among MET exon 14 skipping mutations, MET amplification, c-Met protein overexpression, and MET gene fusions....
In this video, Jamie Chaft, MD, explains why “MET-positive” is not a single biological category and why clinicians should distinguish among MET exon 14 skipping mutations, MET amplification, c-Met protein overexpression, and MET gene fusions....
In this video, Jamie Chaft, MD,...
08/05/2026
Oncology
Videos
08/05/2026
Jamie Chaft, MD
In this video, Jamie Chaft, MD, discusses why tissue acquisition in NSCLC is more than a diagnostic step—it is the foundation for histologic classification, staging, and comprehensive biomarker testing. She highlights how upfront tissue...
In this video, Jamie Chaft, MD, discusses why tissue acquisition in NSCLC is more than a diagnostic step—it is the foundation for histologic classification, staging, and comprehensive biomarker testing. She highlights how upfront tissue...
In this video, Jamie Chaft, MD,...
08/05/2026
Oncology
Thumbnail
Videos
07/30/2026
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to operationalize subcutaneous immunotherapy in clinical practice, covering efficacy and safety review, insurance and workflow considerations, and strategies for educating patients and care teams during the transition.
The panel outlines how to...
07/30/2026
Oncology
Thumbnail
Videos
07/30/2026
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
Experts and a patient discuss the practical advantages of subcutaneous immunotherapy for genitourinary cancers, including reduced chair time, less discomfort, and the resulting impact on patient quality of life and treatment burden.
Experts and a patient discuss the practical advantages of subcutaneous immunotherapy for genitourinary cancers, including reduced chair time, less discomfort, and the resulting impact on patient quality of life and treatment burden.
Experts and a patient discuss...
07/30/2026
Oncology
Thumbnail
Videos
07/30/2026
Meagan Farnie, BSN, RN; Pablo Saenz, PharmD; Dean Tuel; Jeff Yorio, MD
The panel reviews the clinical data behind subcutaneous pembrolizumab and nivolumab, comparing efficacy and pharmacokinetics to their IV counterparts, and shares early clinical impressions of introducing these formulations into practice.
The panel reviews the clinical data behind subcutaneous pembrolizumab and nivolumab, comparing efficacy and pharmacokinetics to their IV counterparts, and shares early clinical impressions of introducing these formulations into practice.
The panel reviews the clinical...
07/30/2026
Oncology
Brigitta Baumert, MD, PhD
Videos
07/28/2026
Brigitta Baumert, MD, PhD
Brigitta Baumert, MD, PhD, discusses long-term results from the phase 3 EORTC 22033-26033 trial comparing upfront radiotherapy with temozolomide in patients with clinically high-risk low-grade glioma, highlighting the prognostic value of...
Brigitta Baumert, MD, PhD, discusses long-term results from the phase 3 EORTC 22033-26033 trial comparing upfront radiotherapy with temozolomide in patients with clinically high-risk low-grade glioma, highlighting the prognostic value of...
Brigitta Baumert, MD, PhD,...
07/28/2026
Oncology

Insights From the ASCO Annual Meeting

News
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses the final overall survival results from the Alliance A081105 ALCHEMIST trial evaluating adjuvant erlotinib after complete resection of stage IB-IIIA EGFR-mutant non-small cell lung cancer (NSCLC). Originally...
Ramaswamy Govindan, MD, discusses the final overall survival results from the Alliance A081105 ALCHEMIST trial evaluating adjuvant erlotinib after complete resection of stage IB-IIIA EGFR-mutant non-small cell lung cancer (NSCLC). Originally...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
12/02/2025
Pasi Jänne, MD, PhD
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
12/02/2025
David Goldstein, MD
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
11/13/2025
Sara Lonardi, MD
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings